All News

Adding Cabometyx to Opdivo and Yervoy tended to improve progression-free survival in patients with advanced kidney cancer, research showed.

Jaktinib significantly improved spleen volume reduction rates compared with hydroxyurea in intermediate- to high-risk myelofibrosis.

The combination of Talzenna and Xtandi was approved for the treatment of adults with HRR gene-mutated metastatic castration-resistant prostate cancer.

Patients with platinum-resistant or refractory ovarian cancer experienced deep responses and survival benefits in a trial assessing immunotherapy with chemotherapy.

We asked our audience what life hacks they learned to make cancer treatment a bit easier. Here’s what they had to say.

After being diagnosed with an incurable cancer, I had to reframe my thinking to focus on the positive.

An expert discusses the ongoing SPARK trial for KRASG12-mutant non-small cell lung cancer, and what she hopes for the future of this patient population.

Watch Dr. Rami Komrokji and Dr. John O. Mascarenhas answer questions about myelofibrosis during the CURE® Educated Patient® MPN Summit.

Patients with a subtype of lymphoma may be able to exclude radiotherapy if they respond to chemoimmunotherapy, although more follow-up is needed to assess potential long-term toxicities.

Here’s an overview of the new cancer regimens that gained Food and Drug Administration (FDA) approval in the spring of this year.

I learned that finding the right kind of support during and after a cancer diagnosis is truly invaluable.

Researchers are looking for other ways to disrupt tumor cells in a way that better engages the immune system by exposing it to tumor antigens.

Watch Dr. John O. Mascarenhas, from Icahn School of Medicine, discuss novel therapies in myelofibrosis during the CURE® Educated Patient® MPN Summit.

Watch Dr. Rami Komrokji, from Moffitt Cancer Center, discuss risk stratification and management of myelofibrosis during the CURE® Educated Patient® MPN Summit.

While my taste buds have returned to normal after cancer treatment, my desire to cook and eat has not.

Watch Dr. Nikolai Podoltsev, Dr. Jerry Spivak and Amy Lane answer questions about polycythemia vera during the CURE® Educated Patient® MPN Summit.

A significant majority of patients with early-stage classical Hodgkin lymphoma demonstrated a complete response to treatment with Adcetris, Opdivo and chemotherapy.

Mental and emotional well-being are crucial to a person’s overall health, and they deserve plenty of attention from patients and providers alike.

I’ve learned that “survivor’s guilt” can be another symptom of our disease.

From Colin McFarlane and John Homme opening up about their cancer diagnoses to Pope Francis visiting a pediatric oncology ward, here’s what’s happening in the cancer space this week.

Columvi is the first bispecific antibody that can be administered to patients with relapsed or refractory diffuse large B-cell lymphoma for a defined period of time.

Watch Dr. Jerry Spivak, from Johns Hopkins University School of Medicine, discuss what is on the horizon in the management of polycythemia vera during the CURE® Educated Patient® MPN Summit.

Most patients with nonmetastatic castration-resistant prostate cancer were able to stay on their therapies long-term, research showed.

Mindfulness meditation can make a big difference in the treatment experience of patients.

I remember hearing somewhere that there’s no such thing as achieving the perfect balance; rather, life itself is an act of constant rebalancing. I've found that to be true in life with cancer.

Findings from a phase 3 trial demonstrated that half of patients with FLT3-ITD-mutant acute myeloid leukemia and detectable minimal residual risk derived a relapse-free survival benefit with Xospata.

Watch Dr. Nikolai Podoltsev, from Yale School of Medicine, discuss the current management of polycythemia vera during the CURE® Educated Patient® MPN Summit.

I didn’t expect to be diagnosed with cancer, never mind end up with four diagnoses over the years. Here is what I learned along the way.

Patients with GIST have more treatment options than ever, with others currently under development.

Genetic testing is the norm for cancer patients with familial history. How did I let it slip through the crack?